- Login
- Register & Subscribe
- Language: EN FR DE
Subscribe to MedNous and get ahead in the business of medical innovation. Subscribe now.
The latest MedNous journal. Subscribe to download.
Free Featured Article
Thursday 26 January 2012
Country: Switzerland
Novartis expects to see a squeeze on margins this year as prices fall for drugs that have recently lost patent protection and more money is invested in new product development. This follows a particularly difficult fourth quarter during which operating income was hit by product cancellations and the suspension of production at a manufacturing site in the US.
“We experienced some disappointments in the fourth quarter with Tekturna/Rasilez and with the need to improve our quality standards at some manufacturing sites,” Joseph Jimenez, the Novartis chief executive, said in a prepared statement that accompanied the release of the company's 2011 results. But he went on to say that Novartis is well-positioned to cope with the loss of patents for old drugs and to discover ne
Visit our news section for more articles.
MedNous is a print publication and a website for everyone involved in medical research in Europe.
The November/December 2011 MedNous features:
The latest MedNous journal. Subscribe to download.
Monday January 23 2012
Wednesday January 11 2012
Wednesday January 4 2012
Tuesday January 3 2012
Sunday January 1 2012